ETFChannel.com
AGEN Description — Agenus Inc

Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Co.'s antibody candidates are balstilimab and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, AGEN1181, which is designed to enhance the magnitude of responses to first-generation anti-CTLA-4 molecules and to expand the population of patients benefiting from anti-CTLA-4 therapy.

Company Name: 
Agenus Inc
Website: 
www.agenusbio.com
Sector: 
Biotechnology
Number of ETFs Holding AGEN: 
24
Total Market Value Held by ETFs: 
$86,552,736.13
Total Market Capitalization: 
$661,000,000
% of Market Cap. Held by ETFs: 
13.09%
 ETF   AGEN Weight   AGEN Amount 
 XBI   0.42%   $27,462,891         
 VTI   0.00%   $18,040,001         
 IWM   0.02%   $15,133,127         
 VXF   0.01%   $8,941,768         
 IWO   0.04%   $5,166,925         
 LABU   0.33%   $2,602,191         
 VHT   0.01%   $1,755,516         
 IWC   0.12%   $1,568,552         
 VTWO   0.02%   $1,511,866         
 IDNA   0.42%   $1,466,888         
List of all 24 ETFs holding AGEN »
Quotes delayed 20 minutes

Email EnvelopeFree AGEN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (4.00 out of 4)
99th percentile
(ranked higher than approx. 99% of all stocks covered)

Analysts Forecast:
AGEN Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding AGEN | Agenus Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.